Results for the six months ended 30 September 2025

AI SummaryClose X

Eco Animal Health Group plc reported a strong first half with revenue increasing 19% to £39.4 million, driven by significant growth in the USA and Canada (up 30% to £11.2 million) and a recovery in China and Japan (up 48% to £12.1 million). Gross margins improved substantially to 49.6% from 40.3%, leading to adjusted EBITDA of £3.0 million, a considerable increase from £0.4 million in the prior year. The company also received a positive opinion from the EMA for its poultry vaccine ECOVAXXIN® MS, with an anticipated EU commercial launch in the second half of 2026. The company expects full-year results to be in line with market expectations.

Disclaimer*

UK 100

Latest directors dealings